美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Daiichi Sankyo Co., Ltd.

24.24

-0.9700-3.85%

成交量：27.23萬

成交額：657.97萬

市值：464.58億

市盈率：32.65

高：24.50

開：24.50

低：23.91

收：25.21

資料載入中...

總覽公司新聞公告

第一三共(DSNKY.US)ADC癌症新藥在中國獲批臨牀

美國OTC市場第一三共盤中異動股價大漲6.75%

美國OTC市場第一三共盤中異動早盤股價大漲5.08%

美國OTC市場第一三共盤中異動早盤快速拉昇6.70%報24.53美元

美國OTC市場第一三共盤中異動早盤股價大跌6.93%

第一三共(DSNKY.US)與阿斯利康(AZN.US)潛在重磅抗癌ADC獲推薦在歐盟上市

修正：第一三共公司第三季度每股收益同比增長至$0.22，銷售額從$3.05B增長至$3.18B

第一三共公司第四季度每股收益0.22美元，同比增長0.10美元，銷售額31.8億美元，同比增長30.5億美元

美國OTC市場第一三共盤中異動快速下跌5.75%

美國OTC市場第一三共盤中異動早盤股價大漲9.26%

第一三共(DSNKY.US)口服抗腫瘤新藥在中國申報上市

阿斯利康(AZN.US)和第一三共(DSNKY.US)的抗體偶聯藥物datopotamab deruxtecan獲FDA優先審評資格

第一三共(DSNKY.US)申報的DS-3939a臨牀試驗申請已獲得受理為該產品首次在中國申報臨牀

美國OTC市場第一三共盤中異動早盤股價大漲5.46%報34.02美元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/DSNKY/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DSNKY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DSNKY\",,,,,undefined,":{"symbol":"DSNKY","market":"US","secType":"STK","nameCN":"Daiichi Sankyo Co., Ltd.","latestPrice":24.24,"timestamp":1743624000000,"preClose":25.21,"halted":0,"volume":272340,"delay":15,"floatShares":1876450459,"shares":1916602000,"eps":0.742527,"marketStatus":"盤前交易","change":-0.97,"latestTime":"04-02 16:00:00 EDT 延時","open":24.5,"high":24.5,"low":23.91,"amount":6579656.188900004,"amplitude":0.023403,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.742527,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1743687000000},"marketStatusCode":1,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":24.24,"volumeRatio":1.0148595651447656},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DSNKY\",,,,,undefined,":{"symbol":"DSNKY","floatShares":1876450459,"roa":"4.94%","roe":"15.29%","lyrEps":0.692127,"volumeRatio":1.0148595651447656,"shares":1916602000,"dividePrice":0.40986,"high":24.5,"amplitude":0.023403,"preClose":25.21,"low":23.91,"week52Low":22.47,"pbRate":"4.19","psRate":"3.79","week52High":42.48,"institutionHeld":0,"latestPrice":24.24,"eps":0.742527,"divideRate":0.016908,"volume":272340,"delay":15,"ttmEps":0.742527,"open":24.5,"prevYearClose":27.29,"prevWeekClose":24.45,"prevMonthClose":23.88,"prevQuarterClose":23.88,"fiveDayClose":24.57,"twentyDayClose":24.275,"sixtyDayClose":27.4,"earningDate":1745424000000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DSNKY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517815279","title":"第一三共(DSNKY.US)ADC癌症新藥在中國獲批臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2517815279","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517815279?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 21:20","pubTimestamp":1741267210,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，3月6日，中国国家药监局药品审评中心官网公示，第一三共申报的1类新药DS-3939a获批临床，拟开发治疗实体瘤。公开资料显示，DS-3939a是一种靶向肿瘤相关MUC1的抗体偶联药物，正在全球范围内处于1/2期临床研究阶段。根据CDE官网查询，本次为该产品首次在中国获批临床。本次这款创新ADC在中国获批临床，意味着其将在中国进入临床研究阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1258792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","ADC","BK4080","DSNKY","BK4231"],"gpt_icon":0},{"id":"2516388637","title":"美國OTC市場第一三共盤中異動 股價大漲6.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516388637","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516388637?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 22:47","pubTimestamp":1741013229,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时47分，美国OTC市场第一三共股票出现波动，股价急速拉升6.75%。截至发稿，该股报24.50美元/股，成交量303股，换手率0.00%，振幅0.00%。美国OTC市场第一三共股票所在的制药行业中，整体涨幅为0.25%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224709a25d44a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303224709a25d44a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DSNKY","BK4007"],"gpt_icon":0},{"id":"2514182100","title":"美國OTC市場第一三共盤中異動 早盤股價大漲5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514182100","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514182100?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 22:49","pubTimestamp":1740494941,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时49分，美国OTC市场第一三共股票出现波动，股价快速拉升5.08%。截至发稿，该股报23.81美元/股，成交量2.3324万股，换手率0.00%，振幅3.88%。美国OTC市场第一三共股票所在的制药行业中，整体涨幅为2.03%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225224901abdc82a5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225224901abdc82a5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DSNKY","BK4007"],"gpt_icon":0},{"id":"2511293355","title":"美國OTC市場第一三共盤中異動 早盤快速拉昇6.70%報24.53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511293355","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511293355?lang=zh_tw&edition=fundamental","pubTime":"2025-02-13 22:46","pubTimestamp":1739457979,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日22时46分，美国OTC市场第一三共股票出现异动，股价大幅上涨6.70%。截至发稿，该股报24.53美元/股，成交量449股，换手率0.00%，振幅0.00%。最近的财报数据显示，该股实现营业收入31.82亿美元，净利润4.06亿美元，每股收益0.22美元，毛利23.39亿美元，市盈率29.86倍。美国OTC市场第一三共股票所在的制药行业中，整体涨幅为0.12%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213224619a244aeec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213224619a244aeec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","DSNKY"],"gpt_icon":0},{"id":"2510303289","title":"美國OTC市場第一三共盤中異動 早盤股價大跌6.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510303289","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510303289?lang=zh_tw&edition=fundamental","pubTime":"2025-02-12 22:47","pubTimestamp":1739371665,"startTime":"0","endTime":"0","summary":"北京时间2025年02月12日22时47分，美国OTC市场第一三共股票出现异动，股价急速下跌6.93%。截至发稿，该股报22.84美元/股，成交量3628股，换手率0.00%，振幅2.28%。美国OTC市场第一三共股票所在的制药行业中，整体涨幅为0.44%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212224745abcc6129&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250212224745abcc6129&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DSNKY","BK4007"],"gpt_icon":0},{"id":"2508318512","title":"第一三共(DSNKY.US)與阿斯利康(AZN.US)潛在重磅抗癌ADC獲推薦在歐盟上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2508318512","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508318512?lang=zh_tw&edition=fundamental","pubTime":"2025-02-02 15:21","pubTimestamp":1738480887,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，第一三共宣布，其与阿斯利康联合开发的抗体偶联药物datopotamab deruxtecan已获欧洲药品管理局人用药品委员会推荐上市，用于治疗不可切除或转移性激素受体阳性、HER2阴性乳腺癌的成年患者，这些患者需已接受过内分泌治疗，并曾接受过至少一线化疗治疗晚期疾病。DXd具有独特的作用机制，与常见化疗药物伊立替康相比，活性提高10倍。阿斯利康和第一三共在2020年7月达成协议，合作开发这款ADC。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1245199.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2417539215.USD","LU0889565916.HKD","LU1829250122.USD","ADC","BK4080","BK4585","BK4231","BK4588","DSNKY","LU2456880835.USD","LU0109394709.USD","LU2462157665.USD","BK4568","LU0320765992.SGD","AZN","LU2236285917.USD","BK4007"],"gpt_icon":0},{"id":"1186586220","title":"修正：第一三共公司第三季度每股收益同比增長至$0.22，銷售額從$3.05B增長至$3.18B","url":"https://stock-news.laohu8.com/highlight/detail?id=1186586220","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186586220?lang=zh_tw&edition=fundamental","pubTime":"2025-01-31 22:06","pubTimestamp":1738332399,"startTime":"0","endTime":"0","summary":"第一三共公司公布季度每股收益为$0.22。这较去年同期每股收益$0.10增长了120%。本季度公司报告销售额为$31.8亿美元。以上内容来自Benzinga Earnings专栏，原文如下：Daiichi Sankyo Co  reported quarterly earnings of $0.22 per share. This is a 120 percent increase over earnings of $0.10 per share from the same period last year. The company reported $3.18 billion in sales this quarter. This is a 4.29 percent increase over sales of $3.05 billion the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSNKY"],"gpt_icon":0},{"id":"1133176895","title":"第一三共公司第四季度每股收益0.22美元，同比增長0.10美元，銷售額31.8億美元，同比增長30.5億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1133176895","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133176895?lang=zh_tw&edition=fundamental","pubTime":"2025-01-31 15:40","pubTimestamp":1738309212,"startTime":"0","endTime":"0","summary":"第一三共公司报告季度每股收益为0.22美元。公司本季度销售额为31.8亿美元，比去年同期的30.5亿美元增长了4.29%。以上内容来自Benzinga Earnings专栏，原文如下：Daiichi Sankyo Co  reported quarterly earnings of $0.22 per share. This is a 120 percent increase over earnings of $0.10 per share from the same period last year. The company reported $3.18 billion in sales this quarter. This is a 4.29 percent increase over sales of $3.05 billion the same period last year.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"第一三共公司第四季度每股收益0.22美元，同比增长0.10美元，销售额31.8亿美元，同比增长30.5亿美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DSNKY"],"gpt_icon":0},{"id":"2507464634","title":"美國OTC市場第一三共盤中異動 快速下跌5.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507464634","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507464634?lang=zh_tw&edition=fundamental","pubTime":"2025-01-29 22:46","pubTimestamp":1738161972,"startTime":"0","endTime":"0","summary":"北京时间2025年01月29日22时46分，美国OTC市场第一三共股票出现异动，股价快速下跌5.75%。截至发稿，该股报27.21美元/股，成交量2377股，换手率0.00%，振幅0.00%。美国OTC市场第一三共股票所在的制药行业中，整体跌幅为0.06%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250129224612abbc5e1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250129224612abbc5e1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","DSNKY"],"gpt_icon":0},{"id":"2505333272","title":"美國OTC市場第一三共盤中異動 早盤股價大漲9.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505333272","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505333272?lang=zh_tw&edition=fundamental","pubTime":"2025-01-21 22:46","pubTimestamp":1737470784,"startTime":"0","endTime":"0","summary":"北京时间2025年01月21日22时46分，美国OTC市场第一三共股票出现异动，股价快速上涨9.26%。截至发稿，该股报29.25美元/股，成交量985股，换手率0.00%，振幅0.95%。美国OTC市场第一三共股票所在的制药行业中，整体涨幅为1.82%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121224624a22a5a80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250121224624a22a5a80&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","DSNKY"],"gpt_icon":0},{"id":"2503299106","title":"第一三共(DSNKY.US)口服抗腫瘤新藥在中國申報上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2503299106","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503299106?lang=zh_tw&edition=fundamental","pubTime":"2025-01-16 21:20","pubTimestamp":1737033637,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月15日，中国国家药监局药品审评中心官网最新公示，第一三共申报的5.1类新药盐酸吡昔替尼胶囊的上市申请已获得受理。公开资料显示，吡昔替尼是一款CSF1R小分子抑制剂，此前已于2019年8月获得美国FDA批准上市，治疗症状性腱鞘巨细胞瘤成人患者。根据FDA彼时的新闻稿介绍，这是其批准的首个治疗TGCT的治疗方法。目前手术是腱鞘巨细胞瘤的标准疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1239016.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","DSNKY"],"gpt_icon":0},{"id":"2503578169","title":"阿斯利康(AZN.US)和第一三共(DSNKY.US)的抗體偶聯藥物datopotamab deruxtecan獲FDA優先審評資格","url":"https://stock-news.laohu8.com/highlight/detail?id=2503578169","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503578169?lang=zh_tw&edition=fundamental","pubTime":"2025-01-14 21:20","pubTimestamp":1736860843,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿斯利康和第一三共今日宣布，为抗体偶联药物datopotamab deruxtecan提交的生物制品许可申请已被美国FDA接受，并授予优先审评资格，用于治疗经治局部晚期或转移性表皮生长因子受体突变非小细胞肺癌成年患者。FDA预计将在2025年第三季度完成审评。针对这一患者群体，datopotamab deruxtecan此前已被FDA授予突破性疗法认定。Datopotamab deruxtecan的安全性特征与此前在TROPION-Lung05和TROPION-Lung01试验中的报告一致，未发现新的安全性问题。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1237691.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2236285917.USD","LU2456880835.USD","AZN","LU0320765992.SGD","LU2417539215.USD","LU2462157665.USD","LU0109394709.USD","DSNKY","BK4007","BK4585","LU0889565916.HKD","LU1829250122.USD","BK4588","BK4568"],"gpt_icon":0},{"id":"2492045127","title":"第一三共(DSNKY.US)申報的DS-3939a臨牀試驗申請已獲得受理  為該產品首次在中國申報臨牀","url":"https://stock-news.laohu8.com/highlight/detail?id=2492045127","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492045127?lang=zh_tw&edition=fundamental","pubTime":"2024-12-19 20:50","pubTimestamp":1734612635,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，今日，中国国家药监局药品审评中心官网公示，第一三共申报的1类新药DS-3939a临床试验申请已获得受理。公开资料显示，DS-3939a是一种靶向TA-MUC1的抗体偶联药物，正在全球范围内处于1/2期临床研究阶段。根据CDE官网查询，本次为该产品首次在中国申报临床。体外研究表明，DS-3939a通过DXD介导的细胞毒作用表现出TA-MUC1依赖性的细胞生长抑制作用。此外，DS-3939a在几种TA-MUC1阳性癌细胞系来源的异种移植模型和各种PDX模型中表现出显著的抗肿瘤作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1227311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","DSNKY","03347","BK1583","BK1576","BK4007"],"gpt_icon":0},{"id":"2479869787","title":"美國OTC市場第一三共盤中異動 早盤股價大漲5.46%報34.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2479869787","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479869787?lang=zh_tw&edition=fundamental","pubTime":"2024-10-30 21:46","pubTimestamp":1730295970,"startTime":"0","endTime":"0","summary":"北京时间2024年10月30日21时46分，美国OTC市场第一三共股票出现异动，股价快速拉升5.46%。截至发稿，该股报34.02美元/股，成交量5.6476万股，换手率0.00%，振幅0.00%。美国OTC市场第一三共股票所在的制药行业中，整体跌幅为6.45%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103021461095bd8ea1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024103021461095bd8ea1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DSNKY","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DSNKY\",params:#limit:5,,,undefined,":[{"date":"2024-07-31","symbol":"DSNKY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722412800000,"name":null,"time":"","dateTimestamp":1722398400000,"actualEps":null},{"market":"US","date":"2024-04-25","symbol":"DSNKY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-01-30","symbol":"DSNKY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1706590800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-07","symbol":"DSNKY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1699333200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-07-31","symbol":"DSNKY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1690776000000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DSNKY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DSNKY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4118,"buy":0.5882,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5882,"analysts":17,"updateTime":1740801600000}}}